Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchNigella SativaNigella Sativa (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta
Home Adoption Other Treatments
Loading...
Analgesics⏵
Antiandrogens⏵
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins⏵

Supplementary Data — Nigella Sativa for COVID-19: real-time meta analysis of 12 studies

@CovidAnalysis, September 2023
Tweet
Share
PDF
Studies
Submit FeedbackFeedback
https://c19early.org/nsmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ HNS-COVID-PK Ashraf (RCT) 82% 0.18 [0.04-0.80] death 2/157 11/156 CT​1​ Improvement, RR [CI] Treatment Control HNS-COVID-PK Ashraf (RCT) 67% 0.33 [0.01-7.99] death 0/107 1/103 CT​1​ HNS-COVID-PK Ashraf (RCT) 79% 0.21 [0.05-0.92] death 2/50 10/53 CT​1​ HNS-COVID-PK Ashraf (RCT) 84% 0.16 [0.11-0.24] no recov. 107 (n) 103 (n) CT​1​ HNS-COVID-PK Ashraf (RCT) 75% 0.25 [0.15-0.41] no recov. 50 (n) 53 (n) CT​1​ HNS-COVID-PK Ashraf (RCT) 82% 0.18 [0.12-0.27] viral+ 107 (n) 103 (n) CT​1​ HNS-COVID-PK Ashraf (RCT) 77% 0.23 [0.14-0.38] viral+ 50 (n) 53 (n) CT​1​ Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Al-Haidari (RCT) 93% 0.07 [0.02-0.30] severe case 2/160 44/259 Aldwihi 24% 0.76 [0.54-1.03] hosp. 85/345 152/393 Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Koshak (RCT) 43% 0.57 [0.42-0.78] no recov. 34/91 60/92 Bencheqr.. (DB RCT) 69% 0.31 [0.01-7.19] hosp. 0/29 1/23 Bencheqr.. (DB RCT) 9% 0.91 [0.48-1.72] no improv. 28 (n) 23 (n) Bencheqr.. (DB RCT) 35% 0.65 [0.29-1.43] no improv. 28 (n) 23 (n) Bencheqr.. (DB RCT) 43% 0.57 [0.22-1.43] viral+ 5/21 8/19 Said (RCT) 77% 0.23 [0.04-1.23] recovery 30 (n) 30 (n) Said (RCT) 89% 0.11 [0.02-0.58] recovery 30 (n) 30 (n) Said (RCT) 80% 0.20 [0.07-0.59] no recov. 30 (n) 30 (n) Said (RCT) 77% 0.23 [0.07-0.70] no recov. 30 (n) 30 (n) Said (RCT) 85% 0.15 [0.04-0.48] no recov. 30 (n) 30 (n) Said (RCT) 90% 0.10 [0.03-0.33] no recov. 30 (n) 30 (n) Said (RCT) 85% 0.15 [0.02-0.74] no recov. 30 (n) 30 (n) Said (RCT) 67% 0.33 [0.05-1.79] no recov. 30 (n) 30 (n) Said (RCT) 58% 0.42 [0.08-1.86] no recov. 30 (n) 30 (n) Said (RCT) 58% 0.42 [0.08-1.86] no recov. 30 (n) 30 (n) Said (RCT) 82% 0.18 [0.02-0.94] no recov. 30 (n) 30 (n) Said (RCT) 86% 0.14 [0.02-0.70] no recov. 30 (n) 30 (n) Said (RCT) 27% 0.73 [0.22-2.40] no recov. 30 (n) 30 (n) Said (RCT) 56% 0.44 [0.12-1.53] no recov. 30 (n) 30 (n) Said (RCT) 80% 0.20 [0.03-0.92] no recov. 30 (n) 30 (n) Said (RCT) 90% 0.10 [0.01-0.66] no recov. 30 (n) 30 (n) Said (RCT) 61% 0.39 [0.13-1.08] viral+ 30 (n) 30 (n) Said (RCT) 85% 0.15 [0.04-0.51] viral+ 30 (n) 30 (n) Said (RCT) 91% 0.09 [0.02-0.30] viral+ 30 (n) 30 (n) Said (RCT) 87% 0.13 [0.03-0.45] viral+ 30 (n) 30 (n) Karimi (RCT) 51% 0.49 [0.09-2.66] death 2/192 4/189 CT​1​ Karimi (RCT) 61% 0.39 [0.08-2.00] ICU 2/192 5/189 CT​1​ Karimi (RCT) 70% 0.30 [0.15-0.61] hosp. 184 (n) 174 (n) CT​1​ Karimi (RCT) 67% 0.33 [0.17-0.65] no recov. 184 (n) 174 (n) CT​1​ Karimi (RCT) 14% 0.86 [0.80-0.93] no recov. 184 (n) 174 (n) CT​1​ Setayesh (RCT) -8% 1.08 [0.07-16.7] death 1/38 1/41 CT​1​ Setayesh (RCT) 27% 0.73 [0.58-0.92] oxygen time 38 (n) 41 (n) CT​1​ Setayesh (RCT) 29% 0.71 [0.63-0.81] hosp. time 38 (n) 41 (n) CT​1​ Al-Haidari 62% 0.38 [0.31-0.46] symp. case 68/188 180/188 Shehab 0% 1.00 [0.36-2.74] severe case 4/39 22/214 Chandra (RCT) 49% 0.51 [0.16-1.59] cases 4/52 8/53 CT​1​ Chandra (RCT) 87% 0.13 [0.02-0.84] cases 1/51 8/53 CT​1​ Chandra (RCT) 74% 0.26 [0.06-1.17] cases 2/51 8/53 CT​1​ Daneshfard (RCT) 34% 0.66 [0.49-0.89] symp. case 37/89 53/84 CT​1​ Daneshfard (RCT) 97% 0.03 [0.00-0.19] symp. case 1/89 35/84 CT​1​ Daneshfard (RCT) 66% 0.34 [0.11-1.04] symp. case 4/89 11/84 CT​1​ Daneshfard (RCT) 62% 0.38 [0.12-1.16] symp. case 4/89 10/84 CT​1​ Daneshfard (RCT) 26% 0.74 [0.50-1.09] symp. case 29/89 37/84 CT​1​ Daneshfard (RCT) -6% 1.06 [0.43-2.62] symp. case 9/89 8/84 CT​1​ Daneshfard (RCT) 79% 0.21 [0.07-0.59] symp. case 4/89 18/84 CT​1​ Daneshfard (RCT) 76% 0.24 [0.09-0.60] symp. case 5/89 20/84 CT​1​ Daneshfard (RCT) 98% 0.02 [0.00-0.31] symp. case 0/89 25/84 CT​1​ Nigella sativa COVID-19 outcomes c19early.org Sep 2023 ​1​ CT: study uses combined treatment Favors nigella sativa Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Tweet
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0